Literature DB >> 24809981

Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO-incompatible haematopoietic stem cell transplantation.

F Khan1, M A Linden, N D Zantek, G M Vercellotti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24809981      PMCID： PMC4608537          DOI： 10.1111/tme.12121

Source DB:  PubMed          Journal:  Transfus Med        ISSN： 0958-7578            Impact factor:   2.019


× No keyword cloud information.
  5 in total

Review 1.  Diagnosis and management of acquired pure red cell aplasia.

Authors:  Kenichi Sawada; Makoto Hirokawa; Naohito Fujishima
Journal:  Hematol Oncol Clin North Am       Date:  2009-04       Impact factor: 3.722

2.  Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO-mismatched allogeneic hematopoietic cell transplant using bortezomib.

Authors:  L-M Poon; L P Koh
Journal:  Bone Marrow Transplant       Date:  2011-08-29       Impact factor: 5.483

3.  Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation.

Authors:  L M Griffith; J P McCoy; C D Bolan; D F Stroncek; A C Pickett; G F Linton; A Lundqvist; R Srinivasan; S F Leitman; R W Childs
Journal:  Br J Haematol       Date:  2005-03       Impact factor: 6.998

4.  Successful treatment of severe ABO antibody-mediated rejection using bortezomib: a case report.

Authors:  S Westphal; S Hansson; G Stelin; J Holgersson; L Mjörnstedt; S Friman
Journal:  Transplant Proc       Date:  2013-04       Impact factor: 1.066

5.  Clinical guide to ABO-incompatible allogeneic stem cell transplantation.

Authors:  Garrett S Booth; Eric A Gehrie; Charles D Bolan; Bipin N Savani
Journal:  Biol Blood Marrow Transplant       Date:  2013-04-06       Impact factor: 5.742
  5 in total
  2 in total

1.  Pulsed-high-dose dexamethasone as a treatment for pure red cell aplasia following ABO-incompatible allogeneic stem cell transplantation.

Authors:  X Yang; M Levis
Journal:  Transfus Med       Date:  2014-08       Impact factor: 2.019

Review 2.  Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question.

Authors:  Javier Marco-Ayala; Inés Gómez-Seguí; Guillermo Sanz; Pilar Solves
Journal:  Bone Marrow Transplant       Date:  2020-11-14       Impact factor: 5.483
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.